As of 2025-12-24, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -18.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 5,900.73 mil USD. KYMR's TTM EBITDA according to its financial statements is -320.14 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.4x | 15.2x |
| Forward P/E multiples | 18.5x - 42.3x | 22.1x |
| Fair Price | (80.80) - (67.18) | (81.46) |
| Upside | -196.7% - -180.4% | -197.5% |
| Date | EV/EBITDA |
| 2025-12-22 | -18.62 |
| 2025-12-19 | -18.54 |
| 2025-12-18 | -17.56 |
| 2025-12-17 | -18.10 |
| 2025-12-16 | -18.58 |
| 2025-12-15 | -18.92 |
| 2025-12-12 | -19.81 |
| 2025-12-11 | -19.39 |
| 2025-12-10 | -19.86 |
| 2025-12-09 | -19.18 |
| 2025-12-08 | -20.85 |
| 2025-12-05 | -14.63 |
| 2025-12-04 | -14.54 |
| 2025-12-03 | -14.49 |
| 2025-12-02 | -14.10 |
| 2025-12-01 | -14.69 |
| 2025-11-28 | -14.91 |
| 2025-11-26 | -14.91 |
| 2025-11-25 | -14.50 |
| 2025-11-24 | -14.40 |
| 2025-11-21 | -14.50 |
| 2025-11-20 | -14.18 |
| 2025-11-19 | -14.23 |
| 2025-11-18 | -14.11 |
| 2025-11-17 | -14.07 |
| 2025-11-14 | -14.25 |
| 2025-11-13 | -13.96 |
| 2025-11-12 | -13.94 |
| 2025-11-11 | -13.90 |
| 2025-11-10 | -13.43 |
| 2025-11-07 | -12.84 |
| 2025-11-06 | -13.37 |
| 2025-11-05 | -13.12 |
| 2025-11-04 | -13.12 |
| 2025-11-03 | -13.08 |
| 2025-10-31 | -13.56 |
| 2025-10-30 | -13.47 |
| 2025-10-29 | -13.15 |
| 2025-10-28 | -13.58 |
| 2025-10-27 | -13.33 |
| 2025-10-24 | -12.82 |
| 2025-10-23 | -12.64 |
| 2025-10-22 | -12.20 |
| 2025-10-21 | -12.77 |
| 2025-10-20 | -13.26 |
| 2025-10-17 | -13.11 |
| 2025-10-16 | -13.25 |
| 2025-10-15 | -13.79 |
| 2025-10-14 | -12.75 |
| 2025-10-13 | -13.12 |